Tumor Counterattack: Fact or Fiction?

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2005 May 13

PMID 15889255

Citations 31

Authors

Frederik H Igney

Peter H Krammer

Affiliations

Soon will be listed here.

Abstract

Cancer development relies on a variety of mechanisms that facilitate tumor growth despite the presence of a functioning immune system. Understanding these mechanisms may foster novel therapeutic approaches for oncology and organ transplantation. By expression of the apoptosis-inducing protein CD95L (FasL, APO-1L, CD178), tumors may eliminate tumor-infiltrating lymphocytes and suppress anti-tumor immune responses, a phenomenon called "tumor counterattack". On the one hand, preliminary evidence of tumor counterattack in human tumors exists, and CD95L expression can prevent T-cell responses in vitro. On the other hand, CD95L-expressing tumors are rapidly rejected and induce inflammation in mice. Here, we summarize and discuss the consequences of CD95L expression of tumor cells and its contribution to immune escape.

Citing Articles

Tumor necrosis factor superfamily signaling: life and death in cancer.

Ababneh O, Nishizaki D, Kato S, Kurzrock R Cancer Metastasis Rev. 2024; 43(4):1137-1163.

PMID: 39363128 PMC: 11554763. DOI: 10.1007/s10555-024-10206-6.

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy.

Nikolouzakis T, Chrysos E, Docea A, Fragkiadaki P, Souglakos J, Tsiaoussis J Cancers (Basel). 2024; 16(11).

PMID: 38893120 PMC: 11171065. DOI: 10.3390/cancers16111995.

The dual role of the CD95 and CD95L signaling pathway in glioblastoma.

Zhang Y, Jin T, Dou Z, Wei B, Zhang B, Sun C Front Immunol. 2022; 13:1029737.

PMID: 36505426 PMC: 9730406. DOI: 10.3389/fimmu.2022.1029737.

Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression.

Pellegrino B, Hlavata Z, Migali C, De Silva P, Aiello M, Willard-Gallo K Mol Diagn Ther. 2021; 25(4):409-424.

PMID: 33974235 PMC: 8249273. DOI: 10.1007/s40291-021-00525-7.

Influence of Microgravity on Apoptosis in Cells, Tissues, and Other Systems In Vivo and In Vitro.

Prasad B, Grimm D, Strauch S, Erzinger G, Corydon T, Lebert M Int J Mol Sci. 2020; 21(24).

PMID: 33317046 PMC: 7764784. DOI: 10.3390/ijms21249373.

References

Martinou J, Green D . Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol. 2001; 2(1):63-7. DOI: 10.1038/35048069. View

Friesen C, Fulda S, Debatin K . Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ. 1999; 6(5):471-80. DOI: 10.1038/sj.cdd.4400512. View

Dulat H, von Grumbkow C, Baars W, Schroder N, Wonigeit K, Schwinzer R . Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells. Eur J Immunol. 2001; 31(7):2217-26. DOI: 10.1002/1521-4141(200107)31:7<2217::aid-immu2217>3.0.co;2-e. View

Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French L . Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996; 274(5291):1363-6. DOI: 10.1126/science.274.5291.1363. View

Bossi G, Griffiths G . Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med. 1999; 5(1):90-6. DOI: 10.1038/4779. View

Drozdzik M, Qian C, Lasarte J, Bilbao R, Prieto J . Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL). Gene Ther. 1999; 5(12):1622-30. DOI: 10.1038/sj.gt.3300763. View

Judge T, Desai N, Yang Z, Rostami S, Alonso L, Zhang H . Utility of adenoviral-mediated Fas ligand gene transfer to modulate islet allograft survival. Transplantation. 1998; 66(4):426-34. DOI: 10.1097/00007890-199808270-00003. View

Igney F, Behrens C, Krammer P . The influence of CD95L expression on tumor rejection in mice. Eur J Immunol. 2003; 33(10):2811-21. DOI: 10.1002/eji.200324176. View

Kurts C, Heath W, Kosaka H, Miller J, Carbone F . The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J Exp Med. 1998; 188(2):415-20. PMC: 2212451. DOI: 10.1084/jem.188.2.415. View

10.

Tada Y, O-Wang J, Takiguchi Y, Tatsumi K, Kuriyama T, Okada S . Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells. J Immunol. 2002; 169(5):2241-5. DOI: 10.4049/jimmunol.169.5.2241. View

11.

Igney F, Krammer P . Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002; 71(6):907-20. View

12.

Khar A, Varalakshmi C, Pardhasaradhi B, Ali A, Kumari A . Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing fas-ligand: a mechanism of immune evasion. Cell Immunol. 1998; 189(2):85-91. DOI: 10.1006/cimm.1998.1367. View

13.

Shudo K, Kinoshita K, Imamura R, Fan H, Hasumoto K, Tanaka M . The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol. 2001; 31(8):2504-11. DOI: 10.1002/1521-4141(200108)31:8<2504::aid-immu2504>3.0.co;2-c. View

14.

Schmitz I, Krueger A, Baumann S, Schulze-Bergkamen H, Krammer P, Kirchhoff S . An IL-2-dependent switch between CD95 signaling pathways sensitizes primary human T cells toward CD95-mediated activation-induced cell death. J Immunol. 2003; 171(6):2930-6. DOI: 10.4049/jimmunol.171.6.2930. View

15.

Kang S, Schneider D, Lin Z, Hanahan D, Dichek D, Stock P . Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med. 1997; 3(7):738-43. DOI: 10.1038/nm0797-738. View

16.

Krueger A, Baumann S, Krammer P, Kirchhoff S . FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol. 2001; 21(24):8247-54. PMC: 99990. DOI: 10.1128/MCB.21.24.8247-8254.2001. View

17.

Kang S, Braat D, Schneider D, ORourke R, Lin Z, Ascher N . A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. Transplantation. 2000; 69(9):1813-7. DOI: 10.1097/00007890-200005150-00014. View

18.

Zhang H, Fleck M, Kern E, Liu D, Wang Y, Hsu H . Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J Clin Invest. 2000; 105(6):813-21. PMC: 377462. DOI: 10.1172/JCI8236. View

19.

Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A . Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J Immunol. 1999; 162(12):7350-7. View

20.

Dhein J, Walczak H, Baumler C, Debatin K, Krammer P . Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 1995; 373(6513):438-41. DOI: 10.1038/373438a0. View